Sixteen percent of all U.S. healthcare expenditures can be attributed to patients failing to properly adhere to their prescriptions. Pharmacists can be an important, and valuable, part of a patient’s care team.
Pharmaceutical Pricing and Medical Innovation
Other featured articles
It’s Hard to Lower Drug Prices, If You Don’t Know What They Are
In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
CBO Estimate on Pelosi Drug Bill Misses its Long-Term Impact on Health
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs
Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best metric to evaluate them?
Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments
Should Congress reauthorize funding for the Patient-Centered Outcomes Research Institute (PCORI)? Professor William Padula writes the PCORI can generate research relevant for shifting to value-based healthcare.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.